» Articles » PMID: 22308038

Crystal Structure of Human Cytochrome P450 2D6 with Prinomastat Bound

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2012 Feb 7
PMID 22308038
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Human cytochrome P450 2D6 contributes to the metabolism of >15% of drugs used in clinical practice. This study determined the structure of P450 2D6 complexed with a substrate and potent inhibitor, prinomastat, to 2.85 Å resolution by x-ray crystallography. Prinomastat binding is well defined by electron density maps with its pyridyl nitrogen bound to the heme iron. The structure of ligand-bound P450 2D6 differs significantly from the ligand-free structure reported for the P450 2D6 Met-374 variant (Protein Data Bank code 2F9Q). Superposition of the structures reveals significant differences for β sheet 1, helices A, F, F', G", G, and H as well as the helix B-C loop. The structure of the ligand complex exhibits a closed active site cavity that conforms closely to the shape of prinomastat. The closure of the open cavity seen for the 2F9Q structure reflects a change in the direction and pitch of helix F and introduction of a turn at Gly-218, which is followed by a well defined helix F' that was not observed in the 2F9Q structure. These differences reflect considerable structural flexibility that is likely to contribute to the catalytic versatility of P450 2D6, and this new structure provides an alternative model for in silico studies of substrate interactions with P450 2D6.

Citing Articles

Allosteric modulation of cytochrome P450 enzymes by the NADPH cytochrome P450 reductase FMN-containing domain.

Burris-Hiday S, Scott E J Biol Chem. 2023; 299(9):105112.

PMID: 37517692 PMC: 10481364. DOI: 10.1016/j.jbc.2023.105112.


Generation of new inhibitors of selected cytochrome P450 subtypes- study.

Danel T, Wojtuch A, Podlewska S Comput Struct Biotechnol J. 2022; 20:5639-5651.

PMID: 36284709 PMC: 9582735. DOI: 10.1016/j.csbj.2022.10.005.


Differential Interactions of Selected Phytocannabinoids with Human CYP2D6 Polymorphisms.

Huff H, Vasan A, Roy P, Kaul A, Tajkhorshid E, Das A Biochemistry. 2021; 60(37):2749-2760.

PMID: 34491040 PMC: 8455456. DOI: 10.1021/acs.biochem.1c00158.


Beyond generative models: superfast traversal, optimization, novelty, exploration and discovery (STONED) algorithm for molecules using SELFIES.

Nigam A, Pollice R, Krenn M, Dos Passos Gomes G, Aspuru-Guzik A Chem Sci. 2021; 12(20):7079-7090.

PMID: 34123336 PMC: 8153210. DOI: 10.1039/d1sc00231g.


Tryptophan-75 Is a Low-Energy Channel-Gating Residue that Facilitates Substrate Egress/Access in Cytochrome P450 2D6.

McCarty K, Ratliff S, Furge K, Furge L Drug Metab Dispos. 2020; 49(3):179-187.

PMID: 33376147 PMC: 7883074. DOI: 10.1124/dmd.120.000274.


References
1.
Wang B, Yang L, Zhang X, Huang S, Bartlam M, Zhou S . New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev. 2009; 41(4):573-643. DOI: 10.1080/03602530903118729. View

2.
Dehal S, Kupfer D . CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 1997; 57(16):3402-6. View

3.
Shin J, Soukhova N, Flockhart D . Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999; 27(9):1078-84. View

4.
Yano J, Hsu M, Griffin K, Stout C, Johnson E . Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol. 2005; 12(9):822-3. DOI: 10.1038/nsmb971. View

5.
Wang A, Savas U, Stout C, Johnson E . Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1. J Biol Chem. 2010; 286(7):5736-43. PMC: 3037686. DOI: 10.1074/jbc.M110.204420. View